Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 754 across all filing types
Latest filing 2024-04-26 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
第二届董事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 14th meeting of the 2nd Board of Directors of 科兴生物制药股份有限公司, held on April 25, 2024. It includes approvals of various reports and proposals related to the 2023 fiscal year, such as the 2023 Annual Report, 2023 Financial Statements, Internal Control Evaluation Report, Profit Distribution Plan, and other governance and operational matters. The document repeatedly states that these reports and proposals will be submitted to the shareholders' meeting for approval and references that the full reports are disclosed separately on the Shanghai Stock Exchange website. The document itself does not contain the full financial statements or substantive financial data but rather the board's resolutions and approvals of these reports. This fits the definition of a Board/Management Information filing (MANG), which covers announcements of board decisions and management changes or approvals. It is not the Annual Report (10-K) itself, nor is it a simple announcement of report publication (RPA) because it contains detailed board resolutions. Therefore, the appropriate classification is MANG with high confidence.
2024-04-26 Chinese
关于与特定对象签署《附生效条件的股份认购协议之终止协议》暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a listed company regarding the termination of a previously agreed share subscription agreement with a specific related party, who is also the company's chairman and controlling shareholder. It details the board and supervisory committee meetings that approved the termination, the nature of the related party transaction, and confirms no disputes or damages to shareholders. The document is a formal disclosure of a corporate action related to capital issuance that was planned but is now terminated. It does not contain financial statements or detailed financial data, nor is it a report or presentation. It is an announcement about a capital/financing update, specifically about the termination of a share subscription agreement and related transaction. The document length is about 2832 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-04-26 Chinese
2023年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告' (Audit Report) and is issued by Da Hua Certified Public Accountants for the fiscal year ending December 31, 2023. It contains detailed audit opinions, key audit matters, and extensive financial statements including consolidated and parent company balance sheets, income statements, cash flow statements, and notes. The content is comprehensive and includes auditor responsibilities, management responsibilities, and detailed financial data. The document length is about 15,000 characters, indicating it is the full audit report and financial statements, not just an announcement or certification. Therefore, this document fits the category of an Audit Report / Information (AR).
2024-04-26 Chinese
关联交易管理制度
Governance Information Classification · 95% confidence The document is titled '关联交易管理制度' which translates to 'Related Party Transaction Management System'. It is a detailed internal policy document outlining the principles, definitions, pricing, decision-making authority, approval procedures, disclosure requirements, exemptions, and responsibilities related to related party transactions within the company. It references relevant laws and regulations, including the Company Law of the People's Republic of China and listing rules of the Shanghai Stock Exchange. The document is a governance and compliance manual rather than a financial report, earnings release, or announcement. It does not contain financial statements, audit opinions, or voting results. It is not a report publication announcement or a regulatory filing in the sense of a compliance document submitted to regulators. Instead, it details the company's internal governance practices regarding related party transactions, which fits the category of Governance Information (CGR). The document length (8673 characters) and content support this classification with high confidence.
2024-04-26 Chinese
2024年第一季度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as the "2024 First Quarter Report" of 科兴生物制药股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data such as revenue, net profit, cash flow, and balance sheet items for the quarter ending March 31, 2024. The report explicitly states it is unaudited and includes comprehensive financial statements and analysis for the quarter. This matches the definition of an Interim / Quarterly Report (IR), which must contain actual financial statements and substantive financial data for a period shorter than a full fiscal year. The document is about 15,000 characters long, which is consistent with a full report rather than a brief announcement or certification. Therefore, the correct classification is IR with high confidence. Q1 2024
2024-04-26 Chinese
非经营性资金占用及其他关联资金往来情况汇总表的专项审计报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审计报告" (special audit report) concerning non-operating fund occupation and other related party fund transactions for the year 2023. It is issued by an accounting firm (DaHua Certified Public Accountants) and references compliance with regulatory guidelines from the China Securities Regulatory Commission and Shanghai Stock Exchange. The document includes detailed tables of fund occupation and related party transactions, and it is a standalone audit report focusing on a specific issue rather than a full annual report or interim report. It is not a general financial statement but a special audit report on related party transactions and fund occupation, which fits the definition of an Audit Report / Information (AR). The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement. Therefore, the correct classification is AR with high confidence. FY 2023
2024-04-26 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.